

Zachary Scott Wallace

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9435564/publications.pdf>

Version: 2024-02-01

126
papers

8,660
citations

81743

39
h-index

48187

88
g-index

131
all docs

131
docs citations

131
times ranked

7199
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Response to: Correspondence on SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease ™ by C<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e131-e131. | 0.5 | 8 |
| 2 | Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry by Sparks<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e158-e158. | 0.5 | 3 |
| 3 | Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis by van Vollenhoven<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e178-e178. | 0.5 | 7 |
| 4 | Assessing the Severity of COVID-19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learning–Derived Chest Radiograph Scores. <i>Arthritis Care and Research</i> , 2023, 75, 657-666. | 1.5 | 8 |
| 5 | Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality. <i>Rheumatology</i> , 2023, 62, 716-725. | 0.9 | 4 |
| 6 | Response to: Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors ™ by Jovani<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e132-e132. | 0.5 | 1 |
| 7 | Response to: COVID-19 in patients with rheumatic diseases: what is the real mortality risk? ™ by Marques<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e135-e135. | 0.5 | 3 |
| 8 | COVID-19 severity in asthma patients: a multi-center matched cohort study. <i>Journal of Asthma</i> , 2022, 59, 442-450. | 0.9 | 22 |
| 9 | Kidney Transplantation and Cardiovascular Events Among Patients With End-stage Renal Disease Due to Lupus Nephritis: A Nationwide Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1829-1834. | 1.5 | 5 |
| 10 | Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2022, 49, 104-109. | 1.0 | 5 |
| 11 | Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 289-291. | 0.5 | 69 |
| 12 | COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114. | 1.0 | 9 |
| 13 | Lifetime Allergy Symptoms in IgG4-related Disease: A Case-control Study. <i>Arthritis Care and Research</i> , 2022, 74, 1188-1195. | 1.5 | 13 |
| 14 | Validation of Antineutrophil Cytoplasmic Antibody-associated Vasculitis as the Cause of End-stage Renal Disease in the US Renal Data System. <i>ACR Open Rheumatology</i> , 2022, 4, 8-12. | 0.9 | 2 |
| 15 | Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133. | 0.9 | 6 |
| 16 | SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis. <i>Arthritis and Rheumatology</i> , 2022, 74, 766-775. | 2.9 | 117 |
| 17 | Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2022, 4, e105-e112. | 2.2 | 16 |
| 18 | Derivation and Validation of Algorithms to Identify Patients With Immunoglobulin G4-related Disease Using Administrative Claims Data. <i>ACR Open Rheumatology</i> , 2022, . . | 0.9 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy. <i>RMD Open</i> , 2022, 8, e002082. | 1.8 | 9 |
| 20 | COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240. | 2.2 | 30 |
| 21 | The impact of COVID-19 on rheumatology trainingâ€”results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac001. | 0.3 | 7 |
| 22 | Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978. | 0.5 | 49 |
| 23 | Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. <i>Rheumatology</i> , 2022, 61, SI151-SI156. | 0.9 | 7 |
| 24 | The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial. <i>Rheumatology and Therapy</i> , 2022, 9, 497-508. | 1.1 | 1 |
| 25 | Coronavirus Disease 2019 Outcomes Among Recipients of <sc>Antiâ€CD20</sc> Monoclonal Antibodies for <sc>Immuneâ€Mediated</sc> Diseases: A Comparative Cohort Study. <i>ACR Open Rheumatology</i> , 2022, 4, 238-246. | 0.9 | 27 |
| 26 | Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, SI143-SI150. | 0.9 | 40 |
| 27 | Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases. <i>Lancet Rheumatology</i> , The, 2022, , . | 2.2 | 0 |
| 28 | SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187. | 1.8 | 34 |
| 29 | DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152025. | 1.6 | 36 |
| 30 | The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1438-1445. | 0.5 | 7 |
| 31 | CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 368-382. | 1.5 | 53 |
| 32 | Response to: â€COVID-19 in patients with rheumatological diseases treated with Anti-TNFâ€™ by Brito et al and â€Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China â€hot spotâ€™ versus in US â€hot spotâ€™: similarities and differencesâ€™ by Zhao et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e64-e64. | 0.5 | 4 |
| 33 | Association of Race and Ethnicity With COVIDâ€19 Outcomes in Rheumatic Disease: Data From the COVIDâ€19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 374-380. | 2.9 | 66 |
| 34 | The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. <i>Rheumatology</i> , 2021, 60, 353-358. | 0.9 | 32 |
| 35 | Antirheumatic Disease Therapies for the Treatment of COVIDâ€19: A Systematic Review and Metaâ€Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47. | 2.9 | 52 |
| 36 | COVIDâ€19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 914-920. | 2.9 | 117 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 660-666. | 0.5 | 74 |
| 38 | The Association Between Physician Gender and Career Advancement Among Academic Rheumatologists in the United States. <i>Arthritis and Rheumatology</i> , 2021, 73, 168-172. | 2.9 | 17 |
| 39 | The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.3-2. | 0.5 | 14 |
| 40 | Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 347-354. | 2.9 | 25 |
| 41 | Management of primary vasculitides with biologic and novel small molecule medications. <i>Current Opinion in Rheumatology</i> , 2021, 33, 8-14. | 2.0 | 1 |
| 42 | Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine. <i>JAMA Internal Medicine</i> , 2021, 181, 284. | 2.6 | 7 |
| 43 | Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e131-e137. | 2.2 | 61 |
| 44 | Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. <i>Genome Medicine</i> , 2021, 13, 35. | 3.6 | 26 |
| 45 | ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry. <i>Journal of Rheumatology</i> , 2021, 48, 1060-1064. | 1.0 | 5 |
| 46 | COVID-19 and rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2021, 33, 255-261. | 2.0 | 32 |
| 47 | Topic modeling to characterize the natural history of ANCA-Associated vasculitis from clinical notes: A proof of concept study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 150-157. | 1.6 | 5 |
| 48 | The association of smoking with immunoglobulin G4-related disease: a case-control study. <i>Rheumatology</i> , 2021, 60, 5310-5317. | 0.9 | 18 |
| 49 | COVID-19 and Disease-Modifying Anti-rheumatic Drugs. <i>Current Rheumatology Reports</i> , 2021, 23, 28. | 2.1 | 15 |
| 50 | Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146. | 0.5 | 151 |
| 51 | Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 412-418. | 2.0 | 6 |
| 52 | Incident systemic rheumatic disease following COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e402-e404. | 2.2 | 17 |
| 53 | Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. <i>Pancreatology</i> , 2021, 21, 1395-1401. | 0.5 | 20 |
| 54 | Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814. | 1.8 | 121 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e638-e647. | 2.2 | 30 |
| 56 | Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. <i>ACR Open Rheumatology</i> , 2021, 3, 834-841. | 0.9 | 9 |
| 57 | Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology, The</i> , 2021, 3, e707-e714. | 2.2 | 40 |
| 58 | Association of renal transplantation with reduced risk of myocardial infarction and ischemic stroke in ANCA-associated vasculitis: An observational cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1180-1185. | 1.6 | 4 |
| 59 | SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 817-819. | 0.5 | 37 |
| 60 | Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942. | 0.5 | 496 |
| 61 | Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639. | 2.8 | 86 |
| 62 | Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e855-e864. | 2.2 | 38 |
| 63 | Case 37-2021: A 60-Year-Old Man with Fevers, Fatigue, Arthralgias, a Mouth Ulcer, and a Rash. <i>New England Journal of Medicine</i> , 2021, 385, 2282-2293. | 13.9 | 1 |
| 64 | Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2370. | 3.8 | 4 |
| 65 | Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e40-e40. | 0.5 | 4 |
| 66 | Treatment Delays Associated With Prior Authorization for Infusible Medications: A Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 1543-1549. | 1.5 | 20 |
| 67 | An 80-Year-Old Man With Fevers, Altered Mental Status, and Joint Effusions. <i>Arthritis Care and Research</i> , 2020, 72, 293-300. | 1.5 | 1 |
| 68 | Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 201-202. | 2.9 | 0 |
| 69 | Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid. <i>Arthritis and Rheumatology</i> , 2020, 72, 234-241. | 2.9 | 9 |
| 70 | Disease Severity Linked to Increase in Autoantibody Diversity in IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 687-693. | 2.9 | 38 |
| 71 | All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. <i>Rheumatology</i> , 2020, 59, 2308-2315. | 0.9 | 71 |
| 72 | The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 77-87. | 0.5 | 390 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 7-19. | 2.9 | 292 |
| 74 | Prostate and pancreas involvement are linked in IgG4-related disease. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1245-1251. | 1.6 | 7 |
| 75 | Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201. | 1.6 | 19 |
| 76 | The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. <i>Rheumatology</i> , 2020, 59, 1204-1206. | 0.9 | 34 |
| 77 | Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866. | 0.5 | 908 |
| 78 | Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US "hot spot"™. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1156-1162. | 0.5 | 217 |
| 79 | Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 190-195.e2. | 0.5 | 21 |
| 80 | Management of ANCA associated vasculitis. <i>BMJ</i> , The, 2020, 368, m421. | 3.0 | 54 |
| 81 | Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis. <i>ACR Open Rheumatology</i> , 2020, 2, 261-268. | 0.9 | 10 |
| 82 | Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA Internal Medicine</i> , 2020, 180, 870. | 2.6 | 28 |
| 83 | Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253. | 2.2 | 172 |
| 84 | Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , 2020, 7, S85-S88. | 1.3 | 10 |
| 85 | Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 736-745.e6. | 1.5 | 123 |
| 86 | Immunoglobulin G4-related Disease. <i>Clinics in Chest Medicine</i> , 2019, 40, 583-597. | 0.8 | 42 |
| 87 | Phospholipase A2 receptor-associated membranous nephropathy in a patient with IgG4-related disease. <i>Medicine (United States)</i> , 2019, 98, e15616. | 0.4 | 9 |
| 88 | 171. Cardiovascular Disease is the Most Common Cause of Death in ANCA-Associated Vasculitis (AAV). <i>Rheumatology</i> , 2019, 58, . | 0.9 | 2 |
| 89 | 172. The Association of Differences in Lipid Parameters with Disease Activity in ANCA-Associated Vasculitis (AAV). <i>Rheumatology</i> , 2019, 58, . | 0.9 | 0 |
| 90 | Renal Transplantation and Survival Among Patients With Lupus Nephritis. <i>Annals of Internal Medicine</i> , 2019, 170, 240. | 2.0 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887. | 2.9 | 23 |
| 92 | 157-Contemporary prescription opioid use among patients with systemic lupus erythematosus: a population-based cohort study. , 2019, , . | | 0 |
| 93 | Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?. <i>Frontiers in Immunology</i> , 2019, 10, 2855. | 2.2 | 28 |
| 94 | All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014. <i>Arthritis and Rheumatology</i> , 2019, 71, 403-410. | 2.9 | 38 |
| 95 | Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 406-412. | 0.5 | 248 |
| 96 | An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. <i>Arthritis Care and Research</i> , 2018, 70, 1671-1678. | 1.5 | 103 |
| 97 | Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 288-292. | 1.6 | 21 |
| 98 | Improving Mortality in End-Stage Renal Disease Due to Granulomatosis With Polyangiitis (Wegener's) From 1995 to 2014: Data From the United States Renal Data System. <i>Arthritis Care and Research</i> , 2018, 70, 1495-1500. | 1.5 | 10 |
| 99 | Lymphomas in IgG4-related disease: clinicopathologic features in a Western population. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 839-852. | 1.4 | 39 |
| 100 | Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. <i>Arthritis Care and Research</i> , 2018, 70, 445-453. | 1.5 | 12 |
| 101 | Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 394-402. | 0.4 | 61 |
| 102 | Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. <i>Medicine (United States)</i> , 2018, 97, e12631. | 0.4 | 31 |
| 103 | Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1333-1338. | 0.5 | 13 |
| 104 | Case 20-2018: A 64-Year-Old Man with Fever, Arthralgias, and Testicular Pain. <i>New England Journal of Medicine</i> , 2018, 378, 2518-2529. | 13.9 | 1 |
| 105 | Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 737-743.e3. | 2.0 | 54 |
| 106 | Case 15-2017 - A 27-Year-Old Woman with Anemia, Thrombocytosis, and Skin Lesions after Travel Abroad. <i>New England Journal of Medicine</i> , 2017, 376, 1973-1981. | 13.9 | 2 |
| 107 | Emerging Treatment Models in Rheumatology: IgG4-Related Disease: Insights Into Human Immunology and Targeted Therapies. <i>Arthritis and Rheumatology</i> , 2017, 69, 1722-1732. | 2.9 | 46 |
| 108 | Atypical IgG4+ Plasmacytic Proliferations and Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 148, 215-235. | 0.4 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010. | 1.5 | 11 |
| 110 | Nationwide Trends in Hospitalizations and In-Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2017, 69, 915-921. | 1.5 | 32 |
| 111 | Association of IgG4-Related Disease With History of Malignancy. <i>Arthritis and Rheumatology</i> , 2016, 68, 2283-2289. | 2.9 | 90 |
| 112 | Large vessel involvement by IgG4-related disease. <i>Medicine (United States)</i> , 2016, 95, e3344. | 0.4 | 132 |
| 113 | Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 825-838. | 1.5 | 306 |
| 114 | Predictors of disease relapse in IgG4-related disease following rituximab. <i>Rheumatology</i> , 2016, 55, 1000-1008. | 0.9 | 151 |
| 115 | Improved survival in granulomatosis with polyangiitis: A general population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 483-489. | 1.6 | 55 |
| 116 | IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 2466-2475. | 2.9 | 463 |
| 117 | Rituximab for IgG4-related disease: a prospective, open-label trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1171-1177. | 0.5 | 533 |
| 118 | B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2236-2243. | 0.5 | 120 |
| 119 | An update on IgG4-related disease. <i>Current Opinion in Rheumatology</i> , 2015, 27, 83-90. | 2.0 | 39 |
| 120 | Response to: "Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4...years"™ by Yamamoto et al. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e47-e47. | 0.5 | 3 |
| 121 | Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 190-195. | 0.5 | 409 |
| 122 | Ophthalmic manifestations of IgG4-related disease: Single-center experience and literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 806-817. | 1.6 | 182 |
| 123 | De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 679-687. | 1.5 | 302 |
| 124 | IgG4-Related Disease and Hypertrophic Pachymeningitis. <i>Medicine (United States)</i> , 2013, 92, 206-216. | 0.4 | 155 |
| 125 | IgG4-Related Systemic Disease as a Cause of "Idiopathic" Orbital Inflammation, Including Orbital Myositis, and Trigeminal Nerve Involvement. <i>Survey of Ophthalmology</i> , 2012, 57, 26-33. | 1.7 | 144 |
| 126 | Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. <i>Global Rheumatology</i> , 0, | 0.0 | 10 |